Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species
Human CPB2 ELISA Kit for Sandwich ELISA - ABIN414492
Eser, Inegol Gumus, Erdamar, Kaygusuz, Yildirim, Usluogullari, Duran Erdolu, Simavli, Yigitoglu, Ozturk Turhan: Levels of thrombin-activatable fibrinolysis inhibitor and platelet-activating factor in recurrent pregnancy loss patients. in Taiwanese journal of obstetrics & gynecology 2016
Cpb2-deficient mice had decreased pneumococcal meningitis mortality and attenuated cytokine levels and bacterial outgrowth in the syst (show SET ELISA Kits)emic compartment but not in the brain (show CSF2 ELISA Kits)compartment, as compared with wild-type mice.
with strain there was significant PKCepsilon (show PRKCE ELISA Kits) translocation to the Z-disc and co-localization with CapZbeta1 or alpha-actinin (show ACTN1 ELISA Kits), which was quantified on confocal images.
Carboxypeptidase B2 deficiency reveals that complement C3a (show C3 ELISA Kits) limits infection and C5a exacerbates infection in a murine polymicrobial sepsis model.
Combination of TAFI (show SET ELISA Kits)-I and a low dose of rtPA was not as effective as the standard dose of rtPA in treating thromboembolic stroke, while TAFI (show SET ELISA Kits) inhibition alone was not effective at all.
Capping protein-beta (show CAPZB ELISA Kits) knockdown decreases filopodial length, alters filopodial shape, and reduces filopodial dynamics.
In an induced osteoarthritis model, CPB2 knockout mice developed dramatically greater cartilage damage than did wild-type mice, had a greater number of osteophytes, and a greater degree of synovitis.
TAFI (show SET ELISA Kits) deficiency results in accelerated fibrogenesis and increased liver damage in murine models of chronic and acute liver disease, which may be related to increased inflammation.
Actin-capping protein is a novel regulator of microtubule stability that functions by antagonizing mDia1 activity toward actin filaments.
This study suggested that increased expression of TrkB (show NTRK2 ELISA Kits) and Capzb2 accompanies adequate brain reserve in the initial stages of AD pathology.
The unique NFkappaB site in the mouse CPB2 promoter is functional and mediates the upregulation of mouse CPB2 expression by TNFalpha (show TNF ELISA Kits).
TAFIa elicited anti-angiogenic responses by endothelial cells: decreased endothelial cell proliferation, cell invasion, cell migration, tube formation, and collagen degradation. It decreased tube formation and proteolysis in endothelial cell culture grown alone and in co-culture with breast cancer cell lines. TAFIa inhibition increased secretion of matrix metalloprotease proenzymes by endothelial and breast cancer cells.
Plasma levels of TAFI are elevated in patients with chronic thromboembolic pulmonary hypertension and are correlated with resistance to clot (show TXNDC17 ELISA Kits) lysis in those patients.
R12 (show GPR17 ELISA Kits) is a critical residue for the activation of TAFI by thrombin (show F2 ELISA Kits)-thrombomodulin (show THBD ELISA Kits)
Thrombin activatable fibrinolysis inhibitor, particularly its preoperative levels but also levels during the immediate postoperative period, may be key for understanding coagulopathy during liver transplantation, and it may have a role as predictor of increased mortality rates in the liver transplant population
The results suggest that although the TAFI S438G>T polymorphism is not correlated with venous thrombosis risk in all genetic models of venous thrombosis, a trend toward a reduced risk still could be observed. (Meta-analysis)
The results of the present study demonstrated that the CPB2 expression in patients with chronic hepatitis C was inversely correlated with several risk factors of hepatic fibrosis or steatosis, although ectopic CPB2 expression did not suppress the expression of fibrogenic or lipogenic genes.
Protein C (show PROC ELISA Kits) and TAFI are concurrently activated in a thrombomoulin-dependent manner and do not compete for the thrombin (show F2 ELISA Kits)-TM complex, raising the possibility that they interact with distinct activation complexes.
Acute myocardial infarction patients have higher plasma CPU levels and lower proCPU levels than controls. This finding indicates in vivo generation of functional active CPU in patients with AMI (show CFD ELISA Kits).
Arg12-Glu28 and Cys383-Val401 in TAFI are involved in thrombomodulin (show THBD ELISA Kits)-mediated TAFI activation. Gly205-Asp232 is involved in binding to thrombin (show F2 ELISA Kits).
CPB2 polymorphisms (reference sequences: rs1926447 and rs3742264) were related to systemic complications in bacterial meningitis. TAFI levels correlated positively with CSF (show CSF2 ELISA Kits) complement. rs1926447 (TT) was associated with higher levels of TAFI in CSF (show CSF2 ELISA Kits).
analysis of the crystal structure of thrombin-activable fibrinolysis inhibitor (TAFI) and description of the structural basis for its intrinsic activity and the short half-life of TAFIa
Purified bovine TAFI activated in the presence of a proteinaceous inhibitor renders a stable enzyme-inhibitor complex.
Findings presented here suggest that the properties of these two orthologous proteins are similar and that conclusions reached using the bovine TAFI may be extrapolated to the human TAFI protein.
Carboxypeptidases are enzymes that hydrolyze C-terminal peptide bonds. The carboxypeptidase family includes metallo-, serine, and cysteine carboxypeptidases. According to their substrate specificity, these enzymes are referred to as carboxypeptidase A (cleaving aliphatic residues) or carboxypeptidase B (cleaving basic amino residues). The protein encoded by this gene is activated by trypsin and acts on carboxypeptidase B substrates. After thrombin activation, the mature protein downregulates fibrinolysis. Polymorphisms have been described for this gene and its promoter region.
F-actin-capping protein subunit beta
, capZ beta
, capping protein beta 1
, carboxypeptidase B-like protein
, carboxypeptidase B2
, carboxypeptidase B2 (plasma, carboxypeptidase U)
, carboxypeptidase R
, thrombin-activable fibrinolysis inhibitor
, thrombin-activatable fibrinolysis inhibitor
, carboxypeptidase U
, plasma carboxypeptidase B